Zhang Financial LLC Acquires 4,667 Shares of AbbVie Inc. $ABBV

Zhang Financial LLC grew its holdings in AbbVie Inc. (NYSE:ABBV) by 16.0% during the 1st quarter, Holdings Channel reports. The fund owned 33,927 shares of the company’s stock after buying an additional 4,667 shares during the period. Zhang Financial LLC’s holdings in AbbVie were worth $7,379,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of ABBV. Litman Gregory Wealth Management LLC bought a new position in AbbVie in the 4th quarter worth $28,000. Westend Capital Management LLC bought a new stake in AbbVie during the fourth quarter valued at about $29,000. Imprint Wealth LLC increased its position in AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after buying an additional 45 shares in the last quarter. Legacy Wealth Managment LLC ID increased its position in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after buying an additional 73 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in shares of AbbVie in the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Up 0.1%

NYSE ABBV opened at $254.53 on Friday. AbbVie Inc. has a twelve month low of $184.63 and a twelve month high of $261.64. The business has a 50-day moving average price of $229.80 and a 200-day moving average price of $221.94. The firm has a market cap of $449.70 billion, a price-to-earnings ratio of 125.38, a price-to-earnings-growth ratio of 0.84 and a beta of 0.30.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter last year, the company earned $2.46 EPS. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. Research analysts expect that AbbVie Inc. will post 14.16 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Allergan Aesthetics unit won European Commission approval for Boey® (trenibotulinumtoxinE), a new facial injectable for glabellar lines. The approval gives AbbVie a differentiated aesthetics product in all 30 EEA countries and could add another growth driver to offset Humira-related declines. Article Title
• Positive Sentiment: Investors are also focusing on AbbVie’s neuroscience franchise and other newer product catalysts, with analysts expecting solid Q2 growth and continued momentum from brands such as Vyalev, RINVOQ, and SKYRIZI ahead of earnings. Article Title
• Positive Sentiment: Brokerage sentiment remains constructive, with recent coverage showing a “Moderate Buy” consensus and multiple price-target increases in July, reinforcing confidence in AbbVie’s long-term pipeline and earnings outlook. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for AbbVie to $14.08 from $14.23, though the new estimate remains close to the consensus of $14.18 and is not a major deviation. Article Title

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ABBV. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Morgan Stanley raised their target price on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. Finally, Wells Fargo & Company increased their price objective on shares of AbbVie from $260.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday, July 10th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $267.67.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.